company background image
A018620 logo

WooGene B&G KOSDAQ:A018620 Stock Report

Last Price

₩885.00

Market Cap

₩25.6b

7D

0.7%

1Y

-21.9%

Updated

14 Mar, 2025

Data

Company Financials

WooGene B&G Co., Ltd

KOSDAQ:A018620 Stock Report

Market Cap: ₩25.6b

A018620 Stock Overview

Engages veterinary medicines, microbial technology, and vaccines business in South Korea and internationally. More details

A018620 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

WooGene B&G Co., Ltd Competitors

Price History & Performance

Summary of share price highs, lows and changes for WooGene B&G
Historical stock prices
Current Share Price₩885.00
52 Week High₩1,216.00
52 Week Low₩830.00
Beta0.72
1 Month Change-1.88%
3 Month Change-2.32%
1 Year Change-21.89%
3 Year Change-56.19%
5 Year Change-43.63%
Change since IPO-58.13%

Recent News & Updates

These 4 Measures Indicate That WooGene B&G (KOSDAQ:018620) Is Using Debt Extensively

Dec 17
These 4 Measures Indicate That WooGene B&G (KOSDAQ:018620) Is Using Debt Extensively

WooGene B&G Co., Ltd's (KOSDAQ:018620) Share Price Could Signal Some Risk

Aug 06
WooGene B&G Co., Ltd's (KOSDAQ:018620) Share Price Could Signal Some Risk

Recent updates

These 4 Measures Indicate That WooGene B&G (KOSDAQ:018620) Is Using Debt Extensively

Dec 17
These 4 Measures Indicate That WooGene B&G (KOSDAQ:018620) Is Using Debt Extensively

WooGene B&G Co., Ltd's (KOSDAQ:018620) Share Price Could Signal Some Risk

Aug 06
WooGene B&G Co., Ltd's (KOSDAQ:018620) Share Price Could Signal Some Risk

WooGene B&G (KOSDAQ:018620) Takes On Some Risk With Its Use Of Debt

Apr 06
WooGene B&G (KOSDAQ:018620) Takes On Some Risk With Its Use Of Debt

A Look At WooGene B&G's (KOSDAQ:018620) Share Price Returns

Feb 12
A Look At WooGene B&G's (KOSDAQ:018620) Share Price Returns

Would WooGene B&G (KOSDAQ:018620) Be Better Off With Less Debt?

Dec 21
Would WooGene B&G (KOSDAQ:018620) Be Better Off With Less Debt?

Shareholder Returns

A018620KR PharmaceuticalsKR Market
7D0.7%-3.7%-0.3%
1Y-21.9%-1.5%-7.8%

Return vs Industry: A018620 underperformed the KR Pharmaceuticals industry which returned -1.5% over the past year.

Return vs Market: A018620 underperformed the KR Market which returned -7.8% over the past year.

Price Volatility

Is A018620's price volatile compared to industry and market?
A018620 volatility
A018620 Average Weekly Movement2.5%
Pharmaceuticals Industry Average Movement4.5%
Market Average Movement5.7%
10% most volatile stocks in KR Market11.9%
10% least volatile stocks in KR Market2.7%

Stable Share Price: A018620 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A018620's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
197792Seokjin Kangwww.woogenebng.com

WooGene B&G Co., Ltd. engages veterinary medicines, microbial technology, and vaccines business in South Korea and internationally. It offers antibiotic, vaccine, nutrient, anti-inflammation, metabolic stimulant, and iron supplement products for swine, poultry, cattle, aquatic animals, companion animals, and raw materials, as well as operates vaccine research center. The company was formerly known as WooJin Co., Ltd.

WooGene B&G Co., Ltd Fundamentals Summary

How do WooGene B&G's earnings and revenue compare to its market cap?
A018620 fundamental statistics
Market cap₩25.59b
Earnings (TTM)₩1.24b
Revenue (TTM)₩58.64b

20.6x

P/E Ratio

0.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A018620 income statement (TTM)
Revenue₩58.64b
Cost of Revenue₩40.54b
Gross Profit₩18.10b
Other Expenses₩16.86b
Earnings₩1.24b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)42.95
Gross Margin30.86%
Net Profit Margin2.12%
Debt/Equity Ratio40.4%

How did A018620 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/14 09:31
End of Day Share Price 2025/03/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

WooGene B&G Co., Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.